Arcutis Biotherapeutics Inc (ARQT)
9.26
-0.67
(-6.75%)
USD |
NASDAQ |
Nov 15, 16:00
9.25
-0.01
(-0.11%)
After-Hours: 20:00
Arcutis Biotherapeutics Research and Development Expense (TTM): 85.72M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 85.72M |
| June 30, 2024 | 92.45M |
| March 31, 2024 | 98.37M |
| December 31, 2023 | 110.58M |
| September 30, 2023 | 120.68M |
| June 30, 2023 | 164.17M |
| March 31, 2023 | 177.16M |
| December 31, 2022 | 182.44M |
| September 30, 2022 | 201.12M |
| June 30, 2022 | 171.99M |
| March 31, 2022 | 164.55M |
| Date | Value |
|---|---|
| December 31, 2021 | 145.56M |
| September 30, 2021 | 120.37M |
| June 30, 2021 | 112.51M |
| March 31, 2021 | 111.76M |
| December 31, 2020 | 115.31M |
| September 30, 2020 | 98.69M |
| June 30, 2020 | 78.30M |
| March 31, 2020 | 55.50M |
| December 31, 2019 | 36.52M |
| September 30, 2019 | 31.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
36.52M
Minimum
Dec 2019
201.12M
Maximum
Sep 2022
122.19M
Average
113.91M
Median
Research and Development Expense (TTM) Benchmarks
| Mirum Pharmaceuticals Inc | 121.95M |
| Biogen Inc | 2.080B |
| Vertex Pharmaceuticals Inc | 3.456B |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |